FDA approves pancreatic cancer drug that nearly doubles survival

The FDA has approved Rasonque (daraxonrasib) for adults with advanced pancreatic cancer that has stopped responding to earlier treatment, or for patients too sick for standard combination chemotherapy. The drug improved median overall survival to 13.2 months compared with just 6.7 months for standard chemotherapy. It is the first targeted drug approved for pancreatic cancer […] The post FDA approves pancreatic cancer drug that nearly doubles survival appeared first on Becker's Hospita...